New antibody weapon targets tough lymphoma
NCT ID NCT05192486
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 25 times
Summary
This study tests a new drug called GNC-038 in 12 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. It is an early-phase trial to gather important information for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Affiliated Hospital of Hebei University
Baoding, Hebei, China
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
-
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Conditions
Explore the condition pages connected to this study.